Show simple item record

dc.contributor.authorHultcrantz, Malin
dc.contributor.authorWilkes, Sally R
dc.contributor.authorKristinsson, Sigurdur Y
dc.contributor.authorAndersson, Therese M-L
dc.contributor.authorDerolf, Åsa R
dc.contributor.authorEloranta, Sandra
dc.contributor.authorSamuelsson, Jan
dc.contributor.authorLandgren, Ola
dc.contributor.authorDickman, Paul W
dc.contributor.authorLambert, Paul C
dc.contributor.authorBjörkholm, Magnus
dc.date.accessioned2015-07-30T11:28:55Zen
dc.date.available2015-07-30T11:28:55Zen
dc.date.issued2015-07-10en
dc.date.submitted2015en
dc.identifier.citationJ. Clin. Oncol. 2015, 33 (20):2288-95en
dc.identifier.issn1527-7755en
dc.identifier.pmid26033810en
dc.identifier.doi10.1200/JCO.2014.57.6652en
dc.identifier.urihttp://hdl.handle.net/2336/561259en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractMyeloproliferative neoplasms (MPNs) are associated with a shortened life expectancy. We assessed causes of death in patients with MPN and matched controls using both relative risks and absolute probabilities in the presence of competing risks.
dc.description.abstractFrom Swedish registries, we identified 9,285 patients with MPN and 35,769 matched controls. A flexible parametric model was used to estimate cause-specific hazard ratios (HRs) of death and cumulative incidence functions, each with 95% CIs.
dc.description.abstractIn patients with MPN, the HRs of death from hematologic malignancies and infections were 92.8 (95% CI, 70.0 to 123.1) and 2.7 (95% CI, 2.4 to 3.1), respectively. In patients age 70 to 79 years at diagnosis (the largest patient group), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) and 1.5 (95% CI, 1.3 to 1.8), respectively; all were statistically significantly elevated compared with those of controls. In the same age group, no difference was observed in the 10-year probability of death resulting from cardiovascular disease in patients with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%). In patients age 50 to 59 years at diagnosis, the 10-year probability of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% and 1.9% versus 0.4%, respectively. Survival in patients with MPN increased over time, mainly because of decreased probabilities of dying as a result of hematologic malignancies, infections, and, in young patients, cardiovascular disease.
dc.description.abstractPatients with MPN had an overall higher mortality rate than that of matched controls, primarily because of hematologic malignancy, infections, and vascular events in younger patients. Evidently, there is still a need for effective disease-modifying agents to improve patient outcomes.
dc.language.isoenen
dc.publisherGrune & Strattonen
dc.relation.urlhttp://dx.doi.org/ 10.1200/JCO.2014.57.6652en
dc.relation.urlhttp://jco.ascopubs.org/content/33/20/2288.full.pdfen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.subjectKrabbameinen
dc.subjectDánartíðnien
dc.subject.meshMyeloproliferative Disordersen
dc.subject.meshSurvival Rate/trendsen
dc.subject.meshPopulation Surveillanceen
dc.titleRisk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.en
dc.typeArticleen
dc.contributor.departmentKarolinska University Hospital, Karolinska Institutet, South Hospital, Stockholm, Sweden, University of Nottingham, Nottingham , University of Leicester, Leicester, United Kingdom, University of Iceland, Landspitali National University Hospital, Reykjavik, Iceland, Memorial Sloan Kettering Cancer Center, New York, NY., South Hospital, Stockholm, Sweden,en
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractMyeloproliferative neoplasms (MPNs) are associated with a shortened life expectancy. We assessed causes of death in patients with MPN and matched controls using both relative risks and absolute probabilities in the presence of competing risks.
html.description.abstractFrom Swedish registries, we identified 9,285 patients with MPN and 35,769 matched controls. A flexible parametric model was used to estimate cause-specific hazard ratios (HRs) of death and cumulative incidence functions, each with 95% CIs.
html.description.abstractIn patients with MPN, the HRs of death from hematologic malignancies and infections were 92.8 (95% CI, 70.0 to 123.1) and 2.7 (95% CI, 2.4 to 3.1), respectively. In patients age 70 to 79 years at diagnosis (the largest patient group), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) and 1.5 (95% CI, 1.3 to 1.8), respectively; all were statistically significantly elevated compared with those of controls. In the same age group, no difference was observed in the 10-year probability of death resulting from cardiovascular disease in patients with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%). In patients age 50 to 59 years at diagnosis, the 10-year probability of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% and 1.9% versus 0.4%, respectively. Survival in patients with MPN increased over time, mainly because of decreased probabilities of dying as a result of hematologic malignancies, infections, and, in young patients, cardiovascular disease.
html.description.abstractPatients with MPN had an overall higher mortality rate than that of matched controls, primarily because of hematologic malignancy, infections, and vascular events in younger patients. Evidently, there is still a need for effective disease-modifying agents to improve patient outcomes.


This item appears in the following Collection(s)

Show simple item record